ZEAL.CO · PEAD ↑ 100

Zealand Pharma reported Q1 2026 EPS of -5.58 DKK on 2026-05-06, beating the consensus of -9.16 DKK by 3.58 DKK (+39.1%); no prior-year comparable is available in the current feed.

Print-day reaction was +3.2% versus the prior close, as the market absorbed a meaningful EPS beat against a loss-making consensus. The overnight gap to the next open extended a further +7.9%, signalling strong after-hours conviction with no fade. Day 1-to-3 drift added another +0.5%, a modest but positive continuation that left the initial move fully intact. Cumulative abnormal return of +11.3% versus SPY.US decisively clears the PEAD long threshold; the documented drift pattern holds through the window ending 2026-08-03.